Sperlágh B, Vizi E S
Department of Pharmacology, Hungarian Academy of Sciences, Budapest.
Neuroscience. 1992 Nov;51(1):203-9. doi: 10.1016/0306-4522(92)90485-k.
The effects of a variety of alpha 2-adrenoceptor agonists and antagonists were studied on stimulation-evoked release of endogenous ATP, measured by the luciferin-luciferase assay, and on the release of [3H]noradrenaline from the guinea-pig vas deferens. The biphasic mechanical contraction of the guinea-pig smooth muscle was recorded concomitantly. The alpha 2-adrenoceptor agonist, xylazine (1 microM) inhibited the field stimulation-evoked (8 Hz, 0.1 ms, 480 shocks) release of ATP and [3H]noradrenaline, and both phases of the contraction. The inhibitory effect of xylazine on the release of ATP, noradrenaline and muscle contraction was prevented by the selective alpha 2-adrenoceptor antagonist, CH 38083 [7,8-(methylenedioxi)-14 alpha-alloberbanol, 1 microM]. In the presence of prazosin (0.1-1 microM) or WB 4101 [2-(2,6-dimethoxyphenoxyethyl)aminomethyl- 1,4-benzodioxane hydrochloride, 0.1-1 microM], i.e. under the condition when the effect of noradrenaline on postjunctional alpha 1-adrenoceptors was excluded, the stimulation-evoked release of [3H]noradrenaline was significantly enhanced, however, the release of endogenous ATP and also both phases of contraction were reduced. In the presence of prazosin, xylazine was able to inhibit the stimulation-evoked release of ATP. In vas deferens dissected from reserpine pretreated (2 x 5 mg/kg, i.p.) guinea-pigs, the content of noradrenaline was 0.5% of control and there was no detectable evoked release of noradrenaline. Under this condition, the release of ATP evoked by electrical stimulation was still detectable, but the amount of ATP was much smaller than that measured from control animals. Xylazine did not reduce the release of ATP. Oxymetazoline, a relatively selective alpha 2-adrenoceptor agonist failed to inhibit the release of [3H]noradrenaline.(ABSTRACT TRUNCATED AT 250 WORDS)
采用荧光素 - 荧光素酶测定法,研究了多种α₂ - 肾上腺素能受体激动剂和拮抗剂对刺激诱发的内源性ATP释放的影响,以及对豚鼠输精管中[³H]去甲肾上腺素释放的影响。同时记录了豚鼠平滑肌的双相机械收缩。α₂ - 肾上腺素能受体激动剂赛拉嗪(1微摩尔)抑制电场刺激诱发(8赫兹,0.1毫秒,480次电击)的ATP和[³H]去甲肾上腺素释放,以及收缩的两个阶段。选择性α₂ - 肾上腺素能拮抗剂CH 38083 [7,8 - (亚甲二氧基)-14α - 别罗巴诺醇,1微摩尔]可阻止赛拉嗪对ATP、去甲肾上腺素释放及肌肉收缩的抑制作用。在哌唑嗪(0.1 - 1微摩尔)或WB 4101 [2 - (2,6 - 二甲氧基苯氧基乙基)氨基甲基 - 1,4 - 苯并二恶烷盐酸盐,0.1 - 1微摩尔]存在的情况下,即在排除去甲肾上腺素对节后α₁ - 肾上腺素能受体作用的条件下,刺激诱发的[³H]去甲肾上腺素释放显著增强,然而,内源性ATP释放及收缩的两个阶段均减弱。在哌唑嗪存在的情况下,赛拉嗪能够抑制刺激诱发的ATP释放。在从经利血平预处理(2×5毫克/千克,腹腔注射)的豚鼠分离的输精管中,去甲肾上腺素含量为对照的0.5%,且未检测到诱发的去甲肾上腺素释放。在此条件下,电刺激诱发的ATP释放仍可检测到,但ATP量远小于对照动物测得的量。赛拉嗪未减少ATP释放。相对选择性的α₂ - 肾上腺素能受体激动剂羟甲唑啉未能抑制[³H]去甲肾上腺素释放。(摘要截于250字)